Leukapheresis Market
Number of pages: 100 | Report Format: PDF | Published date: April 24, 2023
Historical Years – 2021 | Base Year – 2022 | Forecasted Years – 2023 to 2031
|
Report Attribute |
Details |
|
Market Size Value in 2022 |
US$ 64.7 Million |
|
Revenue Forecast in 2031 |
US$ 139.3 Million |
|
CAGR |
8.9% |
|
Base Year for Estimation |
2022 |
|
Forecast Period |
2023 to 2031 |
|
Historical Year |
2021 |
|
Segments Covered |
Product Type, Application, End User, and Region |
|
Regional Scope |
North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa |
According to the deep-dive market assessment study by Growth Plus Reports, the global leukapheresis market was valued at US$ 64.7 million in 2022 and is expected to register a revenue CAGR of 8.9% to reach US$ 139.3 million by 2031.
Leukapheresis Market Fundamentals
Leukapheresis is a medical procedure in which white blood cells (leukocytes) involved in the body’s immune response are separated from a blood sample. It is a specific form of apheresis in which a blood component, such as red blood cells or platelets, is extracted while the remaining blood is returned to circulation. Leukapheresis is often used to decrease high white blood cell (WBC) counts in chronic lymphocytic leukemia (CLL). It is also used to obtain white blood cells for later transplant and treat steep WBC count decline during cancer chemotherapy. Furthermore, it is also used as part of a novel form of immunotherapy called chimeric antigen receptor (CAR) T-cell therapy to help fight leukemia, prostate cancer, and other forms of cancer.
Leukapheresis can be performed using several methods, including centrifugation, filtration, and immunoadsorption. The choice of method depends on the specific patient’s condition and the purpose of the leukapheresis procedure. Leukapheresis is often used in personalized medicine, as it isolates specific cells for targeted therapy.
[14]
Leukapheresis Market Dynamics
The rising incidence of leukemia and other blood disorders drives the demand for leukapheresis procedures. For instance, according to the American Cancer Society’s article of January 2023, there are around 59,610 new cases of leukemia and 23,710 deaths from leukemia. Additionally, technological advances have improved the efficiency and safety of leukapheresis procedures, making them more widely available and accessible to patients. New technologies such as continuous flow centrifugation and photopheresis are also expanding the application of leukapheresis in treating other diseases, thus helping the growth of the global leukapheresis market. Moreover, leukapheresis is often used as a tool in personalized medicine, as it isolates specific cells for targeted therapy. As personalized medicine becomes more common, the demand for leukapheresis will likely increase, fueling the market’s growth. Rising R&D activities and investments for the development of effective immunotherapies are also likely to play a pivotal role in contributing to the growth of the market revenue.
However, leukapheresis procedures can be expensive, limiting access for some patients, particularly in developing countries or regions with limited healthcare resources. Moreover, despite its potential benefits, leukapheresis is still a relatively new and specialized medical procedure. Awareness and understanding of the procedure among healthcare providers and patients may limit its adoption. Furthermore, while leukapheresis is an effective treatment for certain blood disorders, alternative treatments and technologies are available, such as chemotherapy and stem cell transplantation. These alternatives may limit the demand for leukapheresis in certain patient populations. Potential complications and adverse events and limited awareness and understanding of leukapheresis are some restraints impeding the overall market revenue growth.
Leukapheresis Market Ecosystem
The global leukapheresis market is analyzed from four perspectives: product type, application, end-user, and region.
Leukapheresis Market by Product Type
[11]
Based on the product type, the global leukapheresis market is segmented into leukapheresis devices and leukapheresis disposables.
The leukapheresis disposables segment dominated the market with the principal revenue share in 2022, owing to frequent purchases of disposables compared to devices. These devices include machines and kits that separate white blood cells from the rest of the blood components. Leukapheresis devices can be broadly classified into centrifugation devices and membrane filtration devices. Centrifugation devices use centrifugal force to separate white blood cells from the rest of the blood components. The separated white blood cells are then collected and processed for further use. Examples of centrifugation devices include COBE Spectra Apheresis System, Spectra Optia Apheresis System, and Fresenius Kabi’s COM.TEC.
Similarly, membrane filtration devices use a porous membrane to separate white blood cells from other blood components. These devices are often combined with centrifugation to improve the efficiency of the leukapheresis procedure. Examples of membrane filtration devices include the Cobe 2991, Fenwal Amicus, and Terumo BCT Spectra Optia.
The leukapheresis devices also account for a significant share of the market. The leukapheresis devices refer to the various disposable components and consumables used in the leukapheresis procedure. These disposables include kits, tubing sets, and filters combined with leukapheresis devices to remove white blood cells from the blood. Leukapheresis disposables are often designed to be single-use and disposable to minimize the risk of infection and contamination during the procedure. They are also designed to be compatible with various leukapheresis devices and methods, including centrifugation, membrane filtration, and immunoadsorption. Some examples of leukapheresis disposables include collection bags, kits, filters, and many more.
Leukapheresis Market by Application
Based on the application, the global leukapheresis market is segmented into research and therapeutic applications.
The research application segment accounted for a prominent revenue share of the market in 2022, attributed to rising R&D activities for the development of effective immunotherapies for the treatment of cancer coupled with adopting leukapheresis products for their development. Leukapheresis is often used in research applications to obtain large quantities of specific types of white blood cells for analysis. Alternatively, leukapheresis may collect white blood cells from patients with autoimmune diseases to better understand the disease mechanism and develop new treatments. The leukapheresis procedure can also isolate and collect other types of white blood cells, such as B cells, natural killer cells, and dendritic cells, for research. These cells can be used in various applications, such as vaccine development, drug discovery, and immunological research. These factors contribute to the revenue growth of the research application segment.
The hospitals and transfusion centers accounted for a prominent market revenue share in 2022. Leukapheresis is used in hospitals and transfusion centers to treat various medical disorders such as leukemia, lymphoma, autoimmune diseases, and solid tumors. In hospitals, leukapheresis is often a preparatory treatment before stem cell transplantation. In this procedure, white blood cells are collected from the patient and processed to remove cancerous cells. The remaining white blood cells, including stem cells, are then reinfused into the patient to rebuild the immune system. Leukapheresis is also used in hospitals to treat patients with autoimmune diseases, such as multiple sclerosis, systemic lupus erythematosus, and rheumatoid arthritis. In these cases, leukapheresis is used to remove harmful autoantibodies from the patient’s blood, which can help to reduce inflammation and improve symptoms. These overall factors contribute to the revenue growth of the hospitals and transfusion centers segment.
Leukapheresis Market by End User
Based on the end user, the global leukapheresis market is segmented into hospitals & transfusion centers, component providers & blood centers, academic & research institutes, and pharmaceutical & biotechnology companies.
The component providers & blood centers segment is a key player in the leukapheresis market with the largest revenue share in 2022, owing to growing awareness of blood donation through blood collection centers and rising demand for blood-related products to treat various clinical conditions such as cancer. The component providers & blood centers refer to the provision of leukapheresis devices, disposables, and other components to blood centers and other organizations involved in collecting and processing blood products. Component providers in the leukapheresis market offer a range of products and services to blood centers and other organizations involved in blood collection and processing. These include leukapheresis devices, disposables, and other components, as well as technical support and training services to ensure the safe and effective use of the products. These overall factors contribute to the revenue growth of the component providers & blood centers segment.
Leukapheresis Market by Region
Based on region, the global leukapheresis market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.
North America dominated the global leukapheresis market with the largest revenue share in 2022, attributed to developed healthcare infrastructure, the growing burden of leukemia, and rising R&D activities. Additionally, companies across the region are continuously involved in partnerships, mergers, and acquisitions, which are also expected to improve the leukapheresis market outlook. For instance, in August 2022, Cryoport, Inc., a global leader in temperature-controlled supply chain solutions for the life sciences industry, announced a strategic partnership with Cell Matters, S.A. to provide the life sciences industry with end-to-end cryopreservation services for leukapheresis-derived therapies supporting both autologous and allogeneic cell therapies. The firms will collaborate to create a commercial strategy for promoting these services.
Leukapheresis Market Competitive Landscape
The prominent players operating in the global leukapheresis market are:
Leukapheresis Market Strategic Developments
The global leukapheresis market was valued at US$ 64.7 million in 2022.
Leukapheresis is a medical procedure in which white blood cells (leukocytes) involved in the body’s immune response are separated from a blood sample.
The expected size of the global leukapheresis market in 2031 is US$ 139.3 million.
The expected revenue CAGR of the leukapheresis market during the forecast period be 8.9% from 2023 to 2031.
Some prominent players operating in the global leukapheresis market are Charles River Laboratories, Haemonetics Corporation, Macopharma, and Miltenyi Biotec.
*Insights on financial performance are subject to the availability of information in the public domain